What Patients Are Saying:
of
patients achieved clinically significant improvements
of
patients were satisfied with their therapy2
"I noticed right away that I was not having my usual accidents. I tell everyone to
try it because it can change your life."
- Jaime
Results and experiences may vary and are unique to each individual.
"The procedure was simple and trial period provided me the symptom relief I
needed. I wanted to get the longer-term therapy as soon as possible. I felt like me again."
- Rosa
Results and experiences may vary and are unique to each individual.
The accounts given are genuine and documented. Each statement represents a unique individual experience and does not provide any indication, guide, warranty, or guarantee as to the response other people may experience. Individual symptoms, situations, and circumstances vary.
1. Axonics internal data on file.
2. Whitehead et al. (2009). Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology.
137(2), 512-517
3. Pezzella A, McCrery R, Lane F, et al. Two-year outcomes of the ARTISAN-SNM study for the treatment of
urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system. Neurourol Urodyn.
2021;40(2):714-721.doi:10.1002/nau.24615
IMPORTANT SAFETY INFORMATION
Indiciations: Axonics SNM Therapy for urinary control is indicated
for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge
incontinence (leakage) and significant symptoms of urgency-frequency, either alone or in combination. Axonics
SNM Therapy for bowel control is indicated for the treatment of chronic fecal incontinence. The therapy should
only be used in patients who have failed or are not candidates or could not tolerate more conservative
treatments.
Contraindictions: Axonics SNM Therapy is contraindicated for patients
who have not demonstrated an appropriate response to test stimulation or patients who are unable to operate
Axonics SNM Therapy.
Warnings: Implantation and use of Axonics Therapy incurs risk beyond
those normally associated with surgery, some of which may necessitate surgical intervention. These risks
include, but are not limited to adverse change in voiding function (bowel and/or bladder), infection, pain or
irritation at the implant site, lead or device migration, electrical shock, change in sensation or magnitude of
stimulation which has been described as uncomfortable (jolting or shocking) by some patients, and heating or
burns at the device site. Results and experiences may vary and are unique to each patient. No promise or
guarantee is made about specific results or experiences. Talk to your doctor about whether Axonics Therapy is
right for you and to discuss the potential risks and benefits.
For more information about safety and potential risks, go to www.axonics.com/isi
Precautions: The safety and effectiveness of Axonics Therapy has not
been established for use in women who are pregnant or in delivery; for pediatric patients (under the age of 18
years for fecal incontinence and under the age of 16 years for overactive bladder and urinary retention); for
patients with neurological diseases, such as multiple sclerosis or diabetes, or for bilateral stimulation.
Caution: U.S. Federal law restricts this device to sale and use by,
or on the order of, a physician.
For a complete listing of indications, contraindications, warnings and precautions, go to www.axonics.com/isi.
© 2024 Axonics, Inc. All rights reserved. 110-0146-078rA